ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in New York, NY

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Psychomotor Agitation
Brain Diseases
Neurodegenerative Diseases

Alzheimer's Disease trials near New York, NY, USA:

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

New York, New York, United States and 39 other locations

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...

Enrolling
Alzheimer Disease 6
Dementia of Alzheimer Type
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active
Cognito Therapeutics
Cognito Therapeutics

Brooklyn, New York, United States of America and 67 other locations

the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's...

Enrolling
Alzheimer Disease
Device: Blood Brain Barrier (BBB) Disruption
InSightec
InSightec

New York, New York, United States and 9 other locations

reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

Phase 3

Lilly
Lilly

Springfield, New Jersey, United States and 75 other locations

Locations recently updated

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies...

Enrolling
Alzheimer's Disease Psychosis
Drug: Placebo
Drug: ACP-204

Phase 2, Phase 3

Acadia Pharmaceuticals
Acadia Pharmaceuticals

Bronx, New York, United States and 108 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

New York, New York, United States and 117 other locations

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

Phase 2

Lilly
Lilly

Springfield, New Jersey, United States and 69 other locations

versus (vs) placebo on the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) up to Week 80 in study participants with prodromal or mild Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Other: Placebo
Biological: Bepranemab

Phase 2

UCB
UCB

Stamford, Connecticut, United States and 102 other locations

Status recently updated

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Active, not recruiting
Alzheimer Disease
Drug: Placebo
Drug: sabirnetug

Phase 2

Acumen Pharmaceuticals

New York, New York, United States and 96 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

New York, New York, United States and 168 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems